Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | S1PR3 | Q99500 | 8/20 | 0.41 |
| ▸ | SCD | O00767 | 2/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.35 |
| ▸ | POLB | P06746 | 1/20 | 0.34 |
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | HPGD | P15428 | 1/20 | 0.33 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
| ▸ | SCN9A | Q15858 | 2/20 | 0.33 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1364957 | 0.88 | S1PR3 (0.41) | S1PR3SCDSCN9A | |
| SCHEMBL1366992 | 0.86 | ALDH1A1 (0.38) | ALDH1A1POLBMAPTRXFP1 | |
| SCHEMBL1367487 | 0.84 | ALDH1A1 (0.36) | S1PR3ALDH1A1POLBLMNAMAPT | |
| SCHEMBL2309159 | 0.83 | S1PR3 (0.38) | S1PR3 | |
| SCHEMBL1366943 | 0.82 | ALDH1A1 (0.37) | ALDH1A1POLBLMNAMAPTTSHR | |
| SCHEMBL1367091 | 0.82 | S1PR3 (0.43) | S1PR3 | |
| SCHEMBL1364898 | 0.81 | ALDH1A1 (0.35) | S1PR3ALDH1A1POLBMAPT | |
| SCHEMBL1367105 | 0.81 | CYP1B1 (0.39) | S1PR3SCN9A | |
| SCHEMBL1945423 | 0.80 | POLB (0.38) | ALDH1A1POLBLMNAMAPTHPGD | |
| SCHEMBL1943743 | 0.80 | POLB (0.35) | ALDH1A1POLBLMNAHPGDTSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110288120-A1 | ISOQUINOLINONE DERIVATIVES AS NK3 ANTAGONISTS | H. LUNDBECK A/S (DK) | 2011-11-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110288120-A1 | ISOQUINOLINONE DERIVATIVES AS NK3 ANTAGONISTS | KCNK3, KCNQ3, KCNN3 | S1PR3 559/4885SCD 4617/4885ALDH1A1 2697/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.